Company news

Harrow, Inc. news in 2024

Harrow, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

November 20, 2024

Harrow Announces Participation in Upcoming Investor Conferences

November 14, 2024

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

November 12, 2024

Harrow Announces Third Quarter 2024 Financial Results

November 12, 2024

Harrow Announces Market Access Wins for VEVYE®

November 11, 2024

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products

November 6, 2024

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

October 30, 2024

Harrow Relaunches TRIESENCE®

October 2, 2024

Harrow Announces Nashville Expansion

September 24, 2024

Harrow to Present at Three Investor Conferences in September in New York

September 2, 2024

Harrow Announces Second Quarter 2024 Financial Results

August 6, 2024

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

July 24, 2024

Harrow to Attend 2024 ASRS Annual Meeting

July 11, 2024

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

July 8, 2024

Harrow Provides TRIESENCE® Relaunch Update

June 19, 2024

Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study

June 4, 2024

Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial

May 12, 2024

Harrow Announces First Quarter 2024 Financial Results

May 12, 2024

Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024

April 24, 2024

Harrow Announces Fourth Quarter and Year-End 2023 Financial Results

March 18, 2024

Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024

March 4, 2024

Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products

February 14, 2024

Harrow Announces New Appointments to its Board of Directors

January 28, 2024

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

January 10, 2024

Melt Pharmaceuticals Provides Corporate Update

January 2, 2024

Harrow Partners with Leading Healthcare Market Access Technology Platforms

January 2, 2024

Calls in 2024

Decks in 2024